by Bacteriophage.news
Bacteriophage.news Contract Manufacturer FAGOFARMA

FAGOFARMA is a Czech company founded in 2013 that is focused on the development and research of bacteriophage-based therapeutics. It has a team of experienced scientists and engineers who are working to develop bacteriophage-based therapeutics for a variety of bacterial infections. The company has a strong focus on preclinical research and serves as CDMO in the field of bacteriophages.

The company is headquartered in Prague, Czech Republic, and also has laboratories in Brno and Ostrava. In 2023, FAGOFARMA has commissioned new GMP certified manufacturing facility in Roztoky near Prague with capacity and capability to provide with bacteriophages for use in human clinical practice. FAGOFARMA’s mission is to develop bacteriophage-based therapeutics that are safe, effective, and affordable. The company believes that bacteriophage therapy has the potential to revolutionize the way that bacterial infections are treated.

FAGOFARMA’s achievements

  • FAGOFARMA has made significant progress in the development of bacteriophage-based therapeutics. The company has a strong preclinical pipeline, and it is currently conducting clinical trials of its lead product.
  • FAGOFARMA is one of few companies in Europe that is GMP certified to manufacture and release bacteriophages for clinical trials and other applications in human medicine.

FAGOFARMA is well-positioned to continue to make progress in the development of bacteriophage-based therapeutics. The company has a strong team, a clear mission, and a track record of achievement. It focuses to be a leading company in the field of bacteriophage therapy. The company is committed to developing safe, effective, and affordable bacteriophage-based therapeutics that can help to address the growing threat of antibiotic resistance.

This website uses cookies. Accept Read More